Changes in tumor size by RECIST correlate with survival

June 13, 2012
Changes in tumor size by RECIST correlate with survival
RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

(HealthDay) -- RECIST categories used to quantify tumor changes during exposure to anticancer therapies correlate well with overall survival (OS) but reflect a more linear continuum without clear inflection points, according to a study published online June 11 in the Journal of Clinical Oncology.

Rajul K. Jain, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues studied the correlation between OS and response, as quantified by RECIST, in 570 participants of 24 phase I oncology trials conducted between October 2004 and May 2009.

The researchers found that 468 of the participants had quantifiable changes in tumor size. Change in tumor size during exposure to anticancer agents, as quantified by RECIST, correlated well with OS in a near-linear fashion without clear inflection points. Residual analyses were used to confirm the association.

"RECIST quantification of response correlates with survival, validating RECIST's use in phase I trials. However, the lack of apparent boundary values in the relationship between change in and OS demonstrates the arbitrary nature of the complete response/partial response/stable disease/ categories and questions emphasis placed on this categorization scheme," the authors write. "Describing tumor responses as a continuous variable may be more informative than reporting categoric responses when evaluating novel ."

One author disclosed a financial tie to Amgen.

Explore further: New criteria for measuring tumor size and progression will help ease workloads in clinical trials

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Investigating better endpoints for immunotherapy trials

September 8, 2010

Cancer immunotherapy calls for revised clinical endpoints that differ from those used for chemotherapy, according to an article published online September 8 in The Journal of the National Cancer Institute.

High survival with surgery in low-risk neuroblastoma

April 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Pancreatectomy OK without downstaging from therapy

May 25, 2012

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May ...

Recommended for you

Oxygen can impair cancer immunotherapy in mice

August 25, 2016

Researchers have identified a mechanism in mice by which anticancer immune responses are inhibited within the lungs, a common site of metastasis for many cancers. This mechanism involves oxygen inhibition of the anticancer ...

Stem cell propagation fuels cancer risk in different organs

August 25, 2016

The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community. Some researchers maintain that environmental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.